Health Care • Biotechnology: Laboratory Analytical Instruments
$0.35 ▼ -0.03
(-8.32%)
MKT CAP: $32.8M • VOL: 6.12M
52W L $0 52W H $19
ROARABLE / RQD
E • 26/100
PIOTROSKI
1 / 9
EYPT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $31.4M | $43.3M | $46.0M |
| YoY Revenue Growth % | -27.5% | -6.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$243.4M | -$145.9M | -$75.1M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$232.0M | -$130.9M | -$70.8M |
| EBITDA (Normalized) | -$240.8M | -$142.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$240.1M | -$126.2M | $1.9M |
| Capital Expenditures (CapEx) | $3.3M | $4.1M | — |
| Free Cash Flow (FCF) | -$243.4M | -$130.3M | $1.9M |
| FCF Margin % | -80.0% | -80.0% | 4.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $101.8M | $99.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $306.1M | $336.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EYPT.